Privi Speciality Chemicals reported robust Q3 and 9M FY26 results, showcasing strong revenue growth and sustained EBITDA margins above 25%. The company is actively pursuing a multi-phase expansion roadmap, including capacity enhancements and new product development, targeting ₹5,000 crores revenue and ₹1,000 crores EBITDA within 3-4 years. The Givaudan JV is progressing well, and the company anticipates benefits from favorable trade policies and its EcoVadis platinum rating, though specific pricing details on contracts remained undisclosed.
vs Q4 FY26
| Metric | Value | YoY |
|---|---|---|
| Total Income (Q3 FY26) | ₹611.15 Cr | +25.0% YoY |
| EBITDA (Q3 FY26) | ₹158 Cr | +37.0% YoY |
| EBITDA Margin (Q3 FY26) | 25.83% | — |
| Adjusted PAT (Q3 FY26) | ₹82 Cr | +86.4% YoY |
| Total Income (9M FY26) | ₹1.9K Cr | +24.0% YoY |
| EBITDA (9M FY26) | ₹481 Cr | +47.0% YoY |
| Category | Headline | |
|---|---|---|
Capex | ₹1,200 crores new plan — 3-phase expansion roadmap · internal accruals and borrowing from the banks | |
Debt | Gross ₹1,000 crores · 1.6x EBITDA | |
M&A | Privi Fine Sciences Private Limited and Privi Biotechnologies Limited merger · pending regulatory |
| Category | Target | Priority |
|---|---|---|
| Profitability | EBITDA Margin→20%-plus | High |
| Profitability | EBITDA Margin→upwards of 20% and less than 27% | Medium |
| Profitability | Prigiv JV Net Profit→achieve net profit | High |
| Profitability | Gross Margins Improvement→100 to 200 basis points and more | Medium |
| Volume | Volume Growth→about 7% | Medium |
| Volume | Volume Growth→between 11% and 15% | Low |
| Capacity | Production Capacity→54,000 metric tons | High |
| Capacity | Capacity Utilization→about 90% | High |
| Long-Term Vision | Revenue→INR5,000 crores | High |
| Long-Term Vision | EBITDA→INR1,000 crores | High |
| New Product Development | Cyclopentanone Production→5,000 tons | Medium |
| New Product Development | Corn Cob Project Launch→launch the project | High |
| New Product Development | Corn Cob Project Scale→20,000 ton level | High |
| Taxation | GST Benefit→full 9% GST benefit for a 20-year period | High |
| # | Metric | |
|---|---|---|
| 01 | Prigiv JV Net Profitability | |
| 02 | Phase 1 Capacity Commercialization | |
| 03 | Overall Volume Growth | |
| 04 | Privi Fine Science Merger Completion | |
| 05 | Corn Cob Project Demonstration/Pilot |
| Severity | Risk |
|---|---|
low | Global Geopolitical Uncertainties Mahesh Babani mentioned 'tariff-related geopolitical uncertainties impacting global trade' but stated the company has shown 'resilient and robust performance'. Management |
medium | World Market Uncertainty and Price Volatility Mahesh Babani noted 'world markets are very uncertain. Sometimes there's a war, sometimes price increases,' but expressed confidence in achieving numbers within a 20-27% EBITDA margin range. Management |
medium | Promoter Share Sale Impact on Market An analyst raised concerns about the promoter share sale. Mahesh Babani explained it was for 'betterment of the market conditions' and 'liquidity in the system', sold to a 'very reputed investor', and that 'leakages which disturbed the market' were uncontrollable. Analyst |
low | New Product Stabilization Issues An analyst inquired about potential stabilization issues for the new product facility coming on stream in Q1 FY28, which was not directly addressed by management. Analyst |
Privi Speciality Chemicals delivered a strong financial performance in Q3 and 9M FY26. Total income for Q3 FY26 grew 25% year-on-year to ₹611.15 crores, while 9M FY26 income increased 24% year-on-year to ₹1,857 crores. EBITDA for Q3 FY26 surged 37% year-on-year to ₹158 crores, resulting in a healthy EBITDA margin of 25.83%. For the nine-month period, EBITDA grew 47% year-on-year to ₹481 crores, with a margin of 25.9%. Adjusted PAT for Q3 FY26 was ₹82 crores, a significant increase from ₹44 crores in the previous year, and for 9M FY26, it reached ₹232 crores, up 84% year-on-year.
The company is actively implementing a clearly defined 3-phase expansion roadmap with a total capital expenditure of ₹1,200 crores over the next 3 years. Phase 1, focused on increasing production capacity for existing products from 48,000 metric tons to 54,000 metric tons, is on schedule for commercialization by March/April 2026. Phases 2 and 3 are dedicated to multi-speciality aroma chemicals, which will add approximately 18,000 metric tons of new capacity. This expansion is crucial for achieving the long-term vision of ₹5,000 crores in revenue and ₹1,000 crores in EBITDA within 3-4 years.
The joint venture with Givaudan, Prigiv, is progressing well and achieved positive EBITDA in Q3 FY26. Management expects Prigiv to achieve net profit in the next financial year, bolstered by a significant ₹150 crores noninterest-bearing trade advance from Givaudan, which will reduce the JV's debt burden and interest costs. An additional ₹50 crores capex for new product manufacturing within Prigiv is being funded through equity infusion (51% Privi, 49% Givaudan).
Privi is investing in biotechnology and new product development, particularly focusing on converting biomass into value-added products. The company is developing Cyclopentanone from renewable resources, aiming to scale production from 500 tons to 5,000 tons within the next two years. Furthermore, a corn cob project, targeting a 20,000-ton production level, is in the laboratory stage with plans for a commercial launch by 2028. These initiatives are expected to generate substantial intellectual property and drive future growth beyond current targets.
The company's ability to maintain strong EBITDA margins, consistently above 20% and over 25% in recent quarters, is attributed to continuous improvements in process yields, reduction in operating costs, and benefits from economies of scale. Management anticipates further gross margin improvement of 100-200 basis points through ongoing R&D and optimization of utility consumption. Privi also expects to benefit from favorable trade arrangements between India, the US, and Europe, and its EcoVadis platinum rating, which could provide duty advantages in export markets.
Privi maintains a conservative approach to debt, with a current gross debt of approximately ₹1,000 crores and a net debt to EBITDA ratio of around 1.6x, well below its target of not exceeding 2.5x. The company plans to fund its ₹1,200 crores capex program primarily through internal accruals and bank borrowings, with management confident that equity dilution will not be necessary. This strategy ensures financial stability while supporting ambitious growth plans.
The amalgamation of Privi Fine Sciences Private Limited and Privi Biotechnologies Limited with Privi Speciality Chemicals Limited is currently in process, with regulatory filings submitted to the stock exchanges. This merger is expected to be completed by October/December 2026, pending NCLT approval. Post-merger, Privi Fine Science is projected to contribute approximately ₹400 crores in revenue, further enhancing the company's scale and product portfolio.